Page last updated: 2024-11-03

riluzole and Spondylosis

riluzole has been researched along with Spondylosis in 4 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Spondylosis: A degenerative spinal disease that can involve any part of the VERTEBRA, the INTERVERTEBRAL DISK, and the surrounding soft tissue.

Research Excerpts

ExcerptRelevanceReference
"Riluzole treatment attenuated oxidative DNA damage in the spinal cord and postoperative decline after decompression surgery."6.80Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. ( Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L, 2015)
"Cervical spondylotic myelopathy (CSM) is the commonest cause of spinal cord impairment worldwide and despite surgical treatment, it is commonly associated with chronic neuropathic pain and neurological impairment."5.40Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. ( Austin, JW; Fehlings, MG; Karadimas, SK; Moon, ES; Yu, WR, 2014)
"To explain the rationale and design of the cervical spondylotic myelopathy (CSM)-Protect clinical trial that aims to elucidate the efficacy and safety of riluzole in the context of CSM."4.89Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial. ( Arnold, PM; Fehlings, MG; Karadimas, SK; Kopjar, B; Wilson, JR, 2013)
"Riluzole treatment attenuated oxidative DNA damage in the spinal cord and postoperative decline after decompression surgery."2.80Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. ( Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L, 2015)
"Cervical spondylotic myelopathy (CSM) is the commonest cause of spinal cord impairment worldwide and despite surgical treatment, it is commonly associated with chronic neuropathic pain and neurological impairment."1.40Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. ( Austin, JW; Fehlings, MG; Karadimas, SK; Moon, ES; Yu, WR, 2014)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Moghaddamjou, A1
Badhiwala, JH1
Fehlings, MG4
Wilson, JR1
Karadimas, SK3
Arnold, PM1
Kopjar, B1
Moon, ES1
Yu, WR1
Austin, JW1
Laliberte, AM1
Tetreault, L1
Chung, YS1
Arnold, P1
Foltz, WD1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study[NCT01257828]Phase 3270 participants (Actual)Interventional2012-03-31Completed
Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471]Phase 3400 participants (Anticipated)Interventional2021-12-22Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for riluzole and Spondylosis

ArticleYear
Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial.
    Spine, 2013, Oct-15, Volume: 38, Issue:22 Suppl 1

    Topics: Cervical Vertebrae; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Neuropro

2013
Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial.
    Spine, 2013, Oct-15, Volume: 38, Issue:22 Suppl 1

    Topics: Cervical Vertebrae; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Neuropro

2013
Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial.
    Spine, 2013, Oct-15, Volume: 38, Issue:22 Suppl 1

    Topics: Cervical Vertebrae; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Neuropro

2013
Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial.
    Spine, 2013, Oct-15, Volume: 38, Issue:22 Suppl 1

    Topics: Cervical Vertebrae; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Neuropro

2013

Trials

1 trial available for riluzole and Spondylosis

ArticleYear
Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy.
    Science translational medicine, 2015, Dec-02, Volume: 7, Issue:316

    Topics: Animals; Axons; Cervical Vertebrae; Decompression, Surgical; Disease Models, Animal; Humans; Magneti

2015

Other Studies

2 other studies available for riluzole and Spondylosis

ArticleYear
Degenerative Cervical Myelopathy: Changing Frontiers.
    World neurosurgery, 2020, Volume: 135

    Topics: Cell- and Tissue-Based Therapy; Cervical Vertebrae; Excitatory Amino Acid Antagonists; Genetic Thera

2020
Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy.
    Neurobiology of disease, 2014, Volume: 62

    Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Gait; Hyperalgesia; Neur

2014